KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:开放图源暂不可得 入排置信度 0.98

Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.

Nicolas Gower, Pierre Feugier, Jason Westin, Jean-Marc Schiano De Colella, Hervé Tilly, M Lia Palomba, Edith Julia, Gandhi-Laurent Damaj, Amandine Durand, Ian Flinn, François Lemonnier, Nadine Morineau, Loic Ysebaert, Nancy Bartlett, Catherine Thieblemont, Vincent Ribrag, Thomas Gastinne, Arthur Dony, Ludovic Fouillet, Stephanie Guidez, Roch Houot, Maria Gomes Da Silva, Jeffrey Barnes, Fontanet Bijou, Guillaume Cartron, Alejandro Martin Garcia-Sancho, Herbert Eradat, Morgane Cheminant, Armando Lopez Guillermo, Pau Abrisqueta, Julie Abraham, Clémentine Sarkozy, Koji Izutsu, Gilles Crochet, Laurie H Sehn, Argyrios Gkasiamis, Marie Laurence Yge, Loic Chartier, Nathan Fowler, Luc Xerri, Gilles Salles, Franck Morschhauser

Blood 147(25) 3061-3068

PMID41915772
PMCID-
DOI10.1182/blood.2026033126
发表日期2026-03-31
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

In the multinational, phase 3 RELEVANCE trial, 1030 patients with previously untreated follicular lymphoma were randomized to receive rituximab + lenalidomide (R2; n = 513) or rituximab-based immunochemotherapy (R-Chemo; n = 517). In the final analysis, at 120 months of follow-up, median progression-free survival (PFS) was comparable between the treatment groups: 110.6 months with R2 vs 102.8 months with R-Chemo, according to the independent review committee assessment. The 10-year PFS rates were 46.4% for R2 and 46.6% for R-chemo. Median overall survival (OS) and time-to-next lymphoma treatment (TTNLT) were not reached in either arm; 10-year OS rates were 82.4% for R2 and 81.1% for R-chemo, and 10-year TTNLT rates were 62.2% for R2 and 66.3% for R-chemo. Overall, patients with progression of disease within 24 months (POD24) had a poorer prognosis than those without POD24 (hazard ratio, 6.215; P< .0001); however, no difference was observed between the study groups. The incidence of second primary malignancies (SPMs) was 2.11 cases per 100 patient-years (95% confidence interval, 1.80-2.46). Only 9 transformations occurred after 24 months (3 with R2 vs 6 with R-chemo). In each study group, 87 patients died, mainly because of lymphoma progression and SPMs. This long-term follow-up of RELEVANCE confirmed that R2 provides a chemotherapy-free alternative to immunochemotherapy in this patient population. This trial was registered at www.clinicaltrials.gov as NCT01476787 and NCT01650701 and at EudraCT as 2011-002792-42.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。